摘要：Arecoline hydrobromide has been used for almost half a century for the treatment of Echinococcus granulosus in dogs. Trials in New Zealand showed that it had real limitations for this purpose. Its main value lies in its use as a diagnostic agent for detecting infections in dogs on a group basis. The data so obtained can be used in educating dog owners as well as for providing base-line data and an index of progress in a continuing control programme. The drug's limitations for treatment and value as a diagnostic agent in a field trial are assessed. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (489K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References . 649 650 651 652
